Improve the treatment available to people with grade 3–4 IDH-mutant astrocytoma.
morca.bio is a mission, not a single product. Today we pursue it with engineered bacteria that ignite the immune system inside the tumor — but the mission is the fixed point. The tool is not.
A mission-driven hub, not a single-asset company.
morca.bio exists to advance treatment for one disease: grade 3–4 IDH-mutant astrocytoma. We run our own programs, and we support and partner on others' — academic labs, CROs, and ventures working the same problem from different angles.
That makes us a hub, not a walled single-asset shop. There may be one track pursued at a time, or several, depending on what the science calls for and where the best work is happening.
A young person's cancer that always comes back.
Grade 3–4 IDH-mutant astrocytoma — the secondary-glioblastoma lineage — typically strikes people in their 30s and 40s. Maximal safe surgery, radiation, and chemotherapy buy time. None of it stops the tumor from returning.
Vorasidenib, the approved IDH inhibitor, blocks new production of the tumor's oncometabolite D-2-HG — it's approved in grade 2 disease and in an ongoing Phase 2 trial for grade 3. But grade 3–4 is a harder problem: D-2-HG is only one of several immunosuppressive mechanisms this tumor uses, so blocking its production alone is less of a complete answer. That gap — a harder disease, a margin nothing can reach — is what this mission targets.
Run what we can. Support what we can't.
Collaborative by design — working with academic groups and CROs, not building a walled single-asset company.
Run
We run our own programs end to end, from mechanism design through preclinical validation, in the open.
Support
We back and partner on programs led by others — academic labs, CROs, and ventures — when their work advances the same mission.
Share
Every program, ours or a partner's, feeds back into what we know about this disease and where the mission should point next.
Engineered bacteria.
Our conviction is engineered bacteria — living, programmable vehicles built to survive only where the tumor is, carry more than one therapeutic payload, and act exactly where surgery and drugs can't reach: the tumor and its infiltrating margin.
We're committed to this approach and to this disease. What stays flexible is how we get there — the programs we run, the partners we back, and the collaborators we support.
This is early-stage science, built on a testable hypothesis and pursued rigorously — not a product available today.
The current tracks.
morca.bio runs its own programs and supports others' — all aimed at the same mission: improving treatment for grade 3–4 IDH-mutant astrocytoma. Today that means engineered, living bacteria. Two tracks are live, at different points on the risk-and-potency curve — two ways into the same tumor.
The make-or-break question
Both share one bet: ignite a controlled immune response at the tumor and let the immune system carry it to the infiltrating margin surgery and drugs can't reach — a question that's directly testable, and the central experimental focus of both programs. Track B also carries an independent floor: by colonizing and destroying the tumor directly, it does real damage even before that bet pays off.
Track A — internal program
Contained cavity depot
A safety-contained probiotic bacterium, placed directly in the surgical resection cavity after tumor removal. It stays alive and active only where the tumor's own oncometabolite, D-2-HG, is present — the same molecule that suppresses the local immune system becomes the cue that keeps the vehicle localized.
There it secretes a payload built to prime an anti-tumor immune response at the resection bed — the tissue closest to where recurrence begins. It's the simpler, gentler approach, with the most straightforward safety story of the two tracks.
Track B — partnership
Tumor-colonizing collaboration
A partnership around a spore-forming bacterium built to germinate and colonize inside the tumor's hypoxic core, not just the resection cavity — using D-2-HG-based sensing to stay contained to tumor tissue.
There it destroys tumor tissue directly, where drugs can't penetrate — valuable on its own — and that destruction also helps ignite an anti-tumor immune response, as a programmable, multi-payload living factory rather than a single-trick construct. It goes deeper into the tumor than Track A: more potential potency, and correspondingly harder safety engineering.
Both tracks are early-stage science, built on a testable hypothesis and pursued rigorously — not a therapy available today. The honest goal is a meaningful, potentially durable response in a subset of patients, in a disease where recurrence has so far been universal.
However you come to this, there's a way to help.
Patients and families, clinicians, scientists and collaborators, supporters and funders — the mission needs all of it.